A one-minute look at managed care news during the week of April 27, 2015, including more good news for the much-anticipated PCSK9 inhibitors and growth in the individual insurance market enrollment.
This week, a meta-analysis in JAMA confirmed that the PCSK9 inhibitors dramatically reduce low-density lipoprotein as well as all-cause mortality and cardiovascular mortality. However, an accompanying editorial cautioned against too much enthusiasm.
A new report from the Kaiser Family Foundation found that enrollment in the individual insurance market grew in 2014 after the first open enrollment period of the Affordable Care Act. Enrollment is expected to continue to grow in 2015, but at a slower pace.
The first videos from the Spring 2015 Oncology Stakeholders Summit is now available online here.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen